Skip to Content

'
John V. Heymach, M.D., Ph.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Office Address

The University of Texas M. D. Anderson Cancer Center
1515 Holcombe Blvd.
Unit Number: 432
Houston, TX 77030
Room Number: FC9.3065
Phone: 713-792-6363
Fax: 713-792-1220
Email: jheymach@mdanderson.org

Education & Training

Degree-Granting Education

1998 Stanford University Medical School, Stanford, CA, MD, Medicine
1996 Stanford University Medical School, Stanford, CA, PHD, Neuroscience
1989 Harvard University, Cambridge, MA, BA, Chemistry

Postgraduate Training

7/2000-6/2003 Clinical Fellowship, Medical Oncology, Dana-Farber/Partners CancerCare Medical Oncology Fellowship Program, Boston, MA, Labortoary Mentor-Judah Folkman, M.D.
7/1999-6/2000 Clinical Residency, Internal Medicine, Brigham and Women′s Hospital, Boston, MA
7/1998-6/1999 Clinical Internship, Internal Medicine, Brigham and Women′s Hospital, Boston, MA

Board Certifications

1/2005 Medical Oncology, American Board of Internal Medicine
1/2002 Internal Medicine, American Board of Internal Medicine

Experience/Service

Academic Appointments

Assistant Professor, Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 7/2005-7/2009

Selected Publications

Peer-Reviewed Original Research Articles
1. Hanrahan EO, Ryan AJ, Mann H, Kennedy SJ, Langmuir P, Natale RB, Herbst RS, Johnson BE, Heymach JV. Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin Cancer Res 15(10):3600-9, 5/2009. e-Pub 5/2009. PMID: 19447868.
2. Zurita AJ, Jonasch E, Wu HK, Tran HT, Heymach JV. Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma. Cancer 115(10 Suppl):2346-54, 5/2009. PMID: 19402074.
3. Naumov GN, Nilsson MB, Cascone T, Briggs A, Straume O, Akslen LA, Lifshits E, Byers LA, Xu L, Wu HK, Jänne P, Kobayashi S, Halmos B, Tenen D, Tang XM, Engelman J, Yeap B, Folkman J, Johnson BE, Heymach JV. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res 15(10):3484-94, 5/2009. e-Pub 5/2009. PMID: 19447865.
4. William WN, Heymach JV, Kim ES, Lippman SM. Molecular targets for cancer chemoprevention. Nat Rev Drug Discov 8(3):213-25, 3/2009. PMID: 19247304.
5. Zhu K, Chan W, Heymach J, Wilkinson M, McConkey DJ. Control of HIF-1alpha expression by eIF2 alpha phosphorylation-mediated translational repression. Cancer Res 69(5). e-Pub 2/2009. PMID: 19244104.
6. Mancuso P, Antoniotti P, Quarna J, Calleri A, Rabascio C, Tacchetti C, Braidotti P, Wu HK, Zurita AJ, Saronni L, Cheng JB, Shalinsky DR, Heymach JV, Bertolini F. Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses. Clin Cancer Res 15(1):267-73, 1/2009. PMID: 19118054.
7. Le XF, Mao W, Lu C, Thornton A, Heymach JV, Sood AK, Bast RC. Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2. Cell Cycle 7(23). e-Pub 12/16/2008. PMID: 19029832.
8. Heymach JV, Paz-Ares L, De Braud F, Sebastian M, Stewart DJ, Eberhardt WE, Ranade AA, Cohen G, Trigo JM, Sandler AB, Bonomi PD, Herbst RS, Krebs AD, Vasselli J, Johnson BE. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 26(33). e-Pub 10/20/2008. PMID: 18936474.
9. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 359(13):1367-80, 9/25/2008. PMID: 18815398.
10. Ren W, Korchin B, Zhu Q-S, Wei C, Dicker A, Heymach JV, Lazar A, Pollock RE, Lev D. Epidermal growth factor receptor (EGFR) blockade in combination with conventional chemotherapy inhibits soft tissue sarcoma (STS) cell growth in vitro and in vivo. Clin Can Res 14(9):2785-2795, 2008.
11. Kim S, Lee S, Greene AK, Arsenault DA, Le H, Meisel J, Novak K, Flynn E, Heymach JV, Puder M. Inhibition of intra-abdominal adhesion formation with the angiogenesis inhibitor sunitinib. J Surg Res 149(1):115-9, 2008. e-Pub 11/21/2007. PMID: 18374947.
12. Beaudry P, Nilsson M, Rioth M, Prox D, Poon D, Xu L, Zweidler-Mckay P, Ryan A, Folkman J, Ryeom S, Heymach J. Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium. Mol Cancer Ther 7(2):418-24, 2008. PMID: 18245671.
13. Heymach JV, Johnson BE, Prager D, Csada E, Roubec J, Pesek M, Spásová I, Belani CP, Bodrogi I, Gadgeel S, Kennedy SJ, Hou J, Herbst RS. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 26(1)(27):165-6, 2008. PMID: 17878479.
14. Gridelli C, Ardizzoni A, Ciardiello F, Hanna N, Heymach JV, Perrone F, Rosell R, Shepherd FA, Thatcher N, Vansteenkiste J, De Petris L, Di Maio M, De Marinis F. Second-line Treatment of Advanced Non-small Cell Lung Cancer. J Thorac Oncol 3(4)(4):430-440, 2008. PMID: 18379366.
15. Cascone T, Morelli MP, Morgillo F, Kim WY, Rodolico G, Pepe S, Berrino L, Lee HY, Heymach JV, Ciardiello F. Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells. J Cell Physiol 216(3):698-707, 2008. PMID: 18381602.
16. Amin DN, Bielenberg DR, Lifshits E, Heymach JV, Klagsbrun M. Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells. Microvasc Res 76(1):15-22, 2008. e-Pub 5/2008. PMID: 18440031.
17. Nikolinakos P, Heymach JV. The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies. J Thorac Oncol 3(6 Suppl 2):S131-4, 2008. PMID: 18520296.
18. Beaudry P, Hida Y, Udagawa T, Alwayn IP, Greene AK, Arsenault D, Folkman J, Heymach JV, Ryeom S, Puder M. Endothelial progenitor cells contribute to accelerated liver regeneration. J Pediatr Surg 42(7):1190-8, 7/2007. PMID: 17618879.
19. Norden-Zfoni A, Desai J, Manola J, Beaudry P, Force J, Maki R, Folkman J, Bello C, Baum C, DePrimo SE, Shalinsky DR, Demetri GD, Heymach JV. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 13(9):2643-50, 5/1/2007. PMID: 17473195.
20. Sakurai MK, Lee S, Arsenault DA, Nose V, Wilson JM, Heymach JV, Puder M. Vascular endothelial growth factor accelerates compensatory lung growth after unilateral pneumonectomy. Am J Physiol Lung Cell Mol Physiol 292(3):L742-7, 3/2007. e-Pub 11/22/2006. PMID: 17122356.
21. Norden-Zfoni A, Desai J, Manola J, Beaudry P, Force J, Maki R, Folkman J, Bello C, Baum C, DePrimo SE, Shalinsky DR, Demetri GD, Heymach JV. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor (GIST). Clin Can Res 13(9):2643-50, 2007.
22. Beaudry P, Hida Y, Udagawa T, Alwayn IP, Greene AK, Arsenault D, Folkman J, Heymach JV, Ryeom S, Puder M. Endothelial progenitor cells contribute to accelerated liver regeneration.Journal of Pediatric surgery. Journal of Pediatric Surgery 42(7):1190-8, 2007.
23. Kamat AA, Kim TJ, Landen CN Jr, Lu C.,Han LY, Lin, YG, Merritt WM, Thaker PH, Gershenson DM, Bischoff FZ, Heymach JV, Jaffe R, Coleman RL, Sood AK. Metronomic Chemotherapy Enhances the Efficacy of Anti-Vascular Therapy in Ovarian Cancer. Cancer Res 67(1)(1):281-8, 2007. PMID: 17210709.
24. Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov GN, Bradner JE, Althaus IW, Gandhi L, Shapiro GI, Nelson JM, Heymach JV, Meyerson M, Wong KK, Jänne PA. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 67(24):281-288, 2007. PMID: 18089823.
25. Lippman SM, Heymach JV. The convergent development of molecular-targeted drugs for cancer treatment and prevention. Clin Cancer Res 13(14):4035-41, 2007. PMID: 17634526.
26. Heymach JV, Johnson BE, Prager D, Csada E, Roubec J, Pesek M, Spásová I, Belani CP, Bodrogi I, Gadgee S, Kennedy SJ, Hou J, Herbst RS. Vandetanib (ZD6474) plus docetaxel in patients with previously treated non-small cell lung cancer: results of arandomized, placebo-controlled phase I/II study. J Clin Oncol 25:4270-4277, 2007.
27. Sakurai MK, Lee S, Arsenault DA, Nose V, Wilson JM, Heymach JV, Puder M. Vascular Endothelial Growth Factor (VEGF) Accelerates Compensatory Lung Growth After Unilateral Pneumonectom. Am J Physiol Lung Cell Mol Physiol 292(3):L742-7, 2007.
28. Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borras AM, Gale CM, Naumov GN, Yeap BY, Jarrell E, Sun J, Tracy S, Zhao X, Heymach JV, Johnson BE, Cantley LC, Janne PA. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR -amplified lung cancer. J Clin Invest 116(10):2695-706, 2006. e-Pub 8/10/2006. PMCID: PMC1570180.
29. Heymach JV, Nilsson M, Blumenschein G, Papadimitrakopoulou V, Herbst R. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin Cancer Res 12(14 Pt 2):4441s-4445s, 2006. PMID: 16857825.
30. Heymach JV, Nilsson M, Blumenschein G, Papadimitrakopoulou V, Herbst R. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin Cancer Res 12:4441s-4445s, 2006. PMID: 16857825.
31. Kulke MH, Bergsland EK, Ryan DP, Enzinger PC, Lynch TJ, Zhu AX, Meyerhardt JA, Heymach JV, Fogler WE, Sidor C, Michelini A, Kinsella K, Venook AP, Fuchs CS. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol 24(22):3555-61, 2006. PMID: 16877721.
32. Lynch TJ, Adjei AA, Bunn PA, Jr, Eisen TG, Engelman J, Goss GD, Haber DA, Heymach JV, Janne PA, Johnson BE, Johnson DH, Lilenbaum RC, Meyerson M, Sandler AB, Sequist LV, Settleman J, Wong KK, Hart CS. Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents. Clin Cancer Res 12(14 Pt 2):4365s-4371s, 2006. PMID: 16857812.
33. Beaudry P, Force J, Naumov GN, Wang A, Baker CH, Ryan A, Soker S, Johnson BE, Folkman J, Heymach JV. Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res 11(9):3514-22, 2005. PMID: 15867254.
34. Davis DW, Takamori R, Raut CP, Xiong HQ, Herbst RS, Stadler WM, Heymach JV, Demetri GD, Rashid A, Shen Y, Wen S, Abbruzzese JL, McConkey DJ. Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668. Clin Cancer Res 11(2 Pt 1):678-89, 2005. PMID: 15701856.
35. Celik I, Surucu O, Dietz C, Heymach JV, Force J, Hoschele I, Becker CM, Folkman J, Kisker O. Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. Cancer Res 65(23):11044-50, 2005. PMID: 16322254.
36. Johnson BE, Heymach JV. Farnesyl transferase inhibitors for patients with lung cancer. Clin Cancer Res 10(12 Pt 2):4254s-4257s, 2004. PMID: 15217969.
37. Heymach JV, Desai J, Manola J, Davis DW, McConkey DJ, Harmon D, Ryan DP, Goss G, Quigley T, Van den Abbeele AD, Silverman SG, Connors S, Folkman J, Fletcher CD, Demetri GD. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin Cancer Res 10(17):5732-40, 2004. PMID: 15355900.
38. Heymach JV, Johnson DH, Khuri FR, Safran H, Schlabach LL, Yunus F, DeVore RF, 3rd, De Porre PM, Richards HM, Jia X, Zhang S, Johnson BE. Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer. Ann Oncol 15(8):1187-93, 2004. PMID: 15277257.
39. Schuch G, Heymach JV, Nomi M, Machluf M, Force J, Atala A, Eder JP, Jr, Folkman J, Soker S. Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells. Cancer Res 63(23):8345-50, 2003. PMID: 14678995.
40. Klein RL, Muir D, King MA, Peel AL, Zolotukhin S, Moller JC, Kruttgen A, Heymach JV, Jr, Muzyczka N, Meyer EM. Long-term actions of vector-derived nerve growth factor or brain-derived neurotrophic factor on choline acetyltransferase and Trk receptor levels in the adult rat basal forebrain. Neuroscience 90(3):815-21, 1999. PMID: 10218782.
41. Kruttgen A, Moller JC, Heymach JV, Jr, Shooter EM. Neurotrophins induce release of neurotrophins by the regulated secretory pathway. Proc Natl Acad Sci U S A 95(16):9614-9, 1998. PMCID: PMC21387.
42. Moller JC, Kruttgen A, Heymach JV, Jr, Ghori N, Shooter EM. Subcellular localization of epitope-tagged neurotrophins in neuroendocrine cells. J Neurosci Res 51(4):463-72, 1998. PMID: 9514200.
43. Heymach JV, Barres BA. Neurotrophins moving forward. Nature 389(6653):789, 791, 10/23/1997. PMID: 9349804.
44. Kruttgen A, Heymach JV, Jr, Kahle PJ, Shooter EM. The role of the nerve growth factor carboxyl terminus in receptor binding and conformational stability. J Biol Chem 272(46):29222-8, 1997. PMID: 9361001.
45. Heymach JV, Jr, Kruttgen A, Suter U, Shooter EM. The regulated secretion and vectorial targeting of neurotrophins in neuroendocrine and epithelial cells. J Biol Chem 271(41):25430-7, 1996. PMID: 8810312.
46. Heymach JV, Barres BA. Neurobiology. Neuronal self-reliance. Nature 374(6521):405-6, 3/30/1995. PMID: 7700345.
47. Heymach JV, Jr, Shooter EM. The biosynthesis of neurotrophin heterodimers by transfected mammalian cells. J Biol Chem 270(20):12297-304, 1995. PMID: 7744882.
48. Suter U, Heymach JV, Jr, Shooter EM. Two conserved domains in the NGF propeptide are necessary and sufficient for the biosynthesis of correctly processed and biologically active NGF. EMBO J 10(9):2395-400, 1991. PMCID: PMC452934.
49. Zage PE, Zeng L, Fang W, Nilsson MB, Heymach JVH, Zweidler-McKay PA. A novel therapeutic combination for neuroblastoma: the VEGFR/EGFR/RET inhibitor vandetanib with 13-cis-retinoic acid. Submitted.
50. Xu L, Nilsson M, Du Z, Cascone T, Herynk M, Nikolinakos P, Oh Y, Hanrahan E, Yang Y, Prudkin L, Liu D, Lee JJ, Johnson F, Wong KK, Girard L, Gazdar A, Minna JD, Kurie J, Wistuba I, Heymach JV. Activated EGFR regulates c-Met expression and invasiveness of non-small cell lung cancer cells through hypoxia-independent regulation of HIF-1a. Submitted.

Invited Articles
1. Naumov GN, Heymach J, Akslen LA. Dr. Folkman's legacy-a life of angiogenesis research. APMIS 116(2):89-92, 2008. PMID: 18321358.
2. Lynch TJ, Blumenschein GR, Engelman JA, Espinoza-Delgado I, Govindan R, Hanke J, Hanna NH, Heymach JV, Hirsch FR, Janne PA, Lilenbaum RC, Natale RB, Riely GJ, Sequist LV, Shapiro GI, Shaw A, Shepherd FA, Socinski M, Sorensen AG, Wakelee HA, Weitzman A. Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy. J Thorac Oncol 3(6 Suppl 2):S107-12, 2008. PMID: 18520291.
3. Byers LA, Heymach JV. Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung cancer. Clin Lung Cancer 8 Suppl 2:S79-85, 2007. PMID: 17382029.
4. Hoque A, Parnes HL, Stefanek ME, Heymach JV, Brown PH, Lippman SM. Meeting Report: Fifth Annual AACR Frontiers in Cancer Prevention Research. Cancer Res 67(19):8989-93, 2007. e-Pub 9/25/2007. PMID: 17895292.
5. Lynch TJ, Bonomi PD, Butts C, Davies AM, Engelman J, Govindan R, Herbst RS, Heymach JV, Johnson BE, Martins RG, Perez-Soler R, Riely GJ, Sandler AB, Sequist LV, Socinski MA, Wong KK, Hart CS. Novel agents in the treatment of lung cancer: Fourth Cambridge Conference. Clin Cancer Res 13(15 Pt 2)(15 Pt 2):s4583-8, 2007. PMID: 17671145.
6. Herbst RS, Heymach JV, O'Reilly MS, Onn A, Ryan AJ. Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Investig Drugs 16(2):239-49, 2007. PMID: 17243944.
7. Hanrahan EO, Heymach JV. Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer. Clin Cancer Res 13(15 Pt 2):s4617-22, 2007. PMID: 17671152.
8. Blumenschein, G., and Heymach, J. V.. Angiogenesis inhibitors for lung cancer: clinical developments and future directions. J Thorac Oncol 1(7):744-8, 2006. PMID: 17409952.
9. Lee D, Heymach JV. Emerging antiangiogenic agents in lung cancer. Clin Lung Cancer 7(5):304-8, 2006. PMID: 16640800.
10. Nilsson M, Heymach JV. Vascular endothelial growth factor (VEGF) pathway. J Thorac Oncol 1(8):768-70, 2006. PMID: 17409958.
11. Heymach JV. ZD6474--clinical experience to date. Br J Cancer 92 Suppl 1:S14-20, 2005. PMID: 15928653.
12. Heymach JV. Angiogenesis and antiangiogenic approaches to sarcomas. Curr Opin Oncol 13(4):261-9, 2001. PMID: 11429484.

Editorials
1. Heymach JV Jr, Barres BA. Neurotrophins moving forward [News and Views]. Nature 389:789-91, 1997.
2. Heymach JV Jr, Barres BA. Neuronal Self Reliance [News and Views]. Nature 374:405-6, 1995.

Abstracts
1. Yordy JS, Byers LA, Davies M, Molkentine D, Nanjundan M, Raju U, Mills G, Minna J, Coombes K, Ang KK, Heymach JV. Reverse Phase Protein Arrays Reveal Biomarkers of Radiation Sensitivity and Resistance in Head and Neck and Lung Cancer Cell Lines. ASTRO Translational Advances in Radiation Oncology and Cancer Imaging Symposium, Alington, Virginia, 2008.
2. Byers L A, Nanjundan M, Girard L, Coombes K R, Xie Y, Peyton M, Ma Y, Zachariah S, Nikolinakos P, Cigarroa R, Mills G B, Roth J A, Minna J D, Heymach J V. Reverse-phase protein array (RPPA) profiling of non-small cell lung cancer lines identifies tumor signatures for sensitivity and resistance to chemotherapy and targeted agents. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research (#3937), 2008.

Book Chapters
1. Heymach JV, Sledge, GW, Jain RK. Tumor Angiogenesis. In: Cancer Medicine. Newgen, 2009.
2. Nilsson M B, Hanrahan E O, Heymach J V. Angiogenesis Inhibitors for the Treatment of Lung Cancer. In: Antiangiogenic Agents in Cancer Therapy. Eds. L. Ellis and B. Teicher. Humana Press: Totwa, NJ, 409-426, 2007.
3. Zurita AJ, Wu HK, Heymach JV. Blood-based biomarkers for VEGF inhibitors. In: Antiangiogenic Cancer Therapy. Ed(s) Davis D W, Herbst R S, Abbruzzese J L. CRC, 517-531, 2007.
4. Hanrahan E, Nilsson M, and Heymach J. Tumor Angiogenesis: Biology and Therapeutic Implications for Lung Cancer. In: Lung Cancer. Blackwell Publishing: Malden, Massachusetts, 369-385, 2007.
5. Heymach JV. Anti-angiogenic Therapy for Cancer: from the Bench to Bedside and Back. In: AACR Education Book, 177-180, 2006.
6. Folkman J, Heymach JV, Kalluri R. Tumor Angiogenesis. In: Cancer Medicine. B.C. Decker, 2005.
7. Heymach JV Folkman J. Tumor Angiogenesis: General Principles and Therapeutic Approaches. In Press. In: Tumor Ablation: Principles and Practice. Springer-Verlag Press, 2005.
8. Suter U, Drinkwater CC, Heymach JV, Lindsay RM, Shooter EM. Investigations on the structure-function relationship of neurotrophins. In: 15th International Symposium on Brain Sciences. Japan Scientific Society Press, 1992.

Books (edited and written)
1. Heymach JV Jr. The biosynthesis, intracellular sorting, and secretion of neurotrophins [Ph.D. dissertation]. Stanford University, 1996.

Grant & Contract Support

Title: Proteomic Profiling of Molecular Pathways Governing Radiation and Drug Sensitivity of Head and Neck and Lung Cancers, no-cost extension
Funding Source: E.L. Wiegand Foundation
Role: Co-Principal Investigators
Principal Investigator: K. Kian Ang
Duration: 7/8/2008 - 12/31/2009
 
Title: Angiogenesis Inhibitors for Lung Cancer: Mechanisms of Resistance, no-cost extension
Funding Source: MDACC
Role: Investigator
Duration: 2007 - 2010
 
Title: VEGFR inhibitors for NSCLC: Clinical studies and novel surrogate markers of activity, no-cost extension
Funding Source: Damon Runyon-Lilly Clinical Investigator Award
Role: Principal Investigator
Duration: 7/1/2004 - 12/31/2009
 
Title: Preclinical and Clinical Studies of Circulating Endothelial Cells as a Surrogate Marker for Antiangiogenic Activity, no-cost extension
Funding Source: American Society of Clinical Oncology Young Investigator Award
Role: Principal Investigator
Duration: 7/1/2003 - 6/30/2004

Last updated: 9/18/2009